Which country is Osimertinib produced in?

Osimertinib (Osimertinib) is an oral third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI), a targeted drug developed by AstraZeneca for the treatment of advanced non-small cell lung cancer (NSCLC). The drug is widely used around the world and approved for marketing in many countries and regions. Specifically, osimertinib has been approved for the treatment of non-small cell lung cancer in China, the United States, Europe and other countries, and is widely used in clinical treatment.

Osimertinib is designed to target the EGFR T790M mutation, which frequently occurs in patients with acquired EGFR TKI-resistant non-small cell lung cancer, while retaining wild-type EGFR. Osimertinib has been shown to give patients more time before their cancer worsens. Median progression-free survival was 18.9 months with osimertinib compared with 10.2 months with standard chemotherapy. Patients treated with osimertinib also lived longer, with median overall survival being 38.6 months with osimertinib compared with 31.8 months with standard chemotherapy.

OsimertinibThe original drug has been launched in China and has been covered by medical insurance. The price of 80mg*30 tablets per box may be around 5,000 yuan, which is relatively expensive. Currently available overseas Osimertinib generics, such as the specifications produced by Bangladesh Pharmaceutical FactoryThe price of each box of 80mg*30 tablets may be more than 800 yuan (the price may fluctuate due to exchange rate effects), which is relatively cheap. Osimertinib generics have basically the same pharmaceutical ingredients as the original drugs sold domestically and abroad. For more drug information and specific prices, please consult Yaode Medical Consultant.